Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for
Advanced Lung Non-Small Cell Carcinoma,
Location: South Weymouth MA, Foxborough MA, Boston MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 70+
Code: NCT06096844
Phase 3, Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
for
Osteoarthritis, Overweight or Obesity
Location: Quincy MA, Burlington MA, Long Island City NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07353931
Phase 3, Recruiting
Shared Online Health Records for Patient Safety and Care
for
Diabetes
Location: Norwood MA, Chestnut Hill MA, Boston MA, Charlestown MA
Sponsor: Agency for Healthcare Research and Quality (AHRQ)
Sex: All
Age: 18+
Code: NCT00251875
Recruiting
Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis
for
Onychomycosis
Location: Quincy MA, College Station TX, McAllen TX
Sponsor: Moe Medical Devices
Sex: All
Age: 18 - 70
Code: NCT02724384
Recruiting
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
for
Netherton Syndrome
Location: Quincy MA, Indianapolis IN, San Diego CA
Sponsor: Quoin Pharmaceuticals
Sex: All
Age: 14+
Code: NCT05789056
Phase 2, Phase 3, Recruiting
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
for
Netherton Syndrome
Location: Quincy MA, Indianapolis IN, San Antonio TX, Fremont CA
Sponsor: Quoin Pharmaceuticals
Sex: All
Age: 4+
Code: NCT07538583
Phase 2, Phase 3, Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
for
Chronic Kidney Disease and Hypertension
Location: Braintree MA, Boston MA, East Providence RI,
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
for
Relapsing Multiple Sclerosis
Location: Foxborough MA, Boston MA, Wellesley MA,
Sponsor: TG Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT05877963
Phase 3, Recruiting
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
for
Attention Deficit Disorder With Hyperactivity (ADHD)
Location: Foxborough MA, East Providence RI, Watertown MA,
Sponsor: Alkermes, Inc.
Sex: All
Age: 18 - 65
Code: NCT07755410
Phase 2, Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
for
Generalized Myasthenia Gravis
Location: Foxborough MA, New Haven CT, New York NY,
Sponsor: Immunovant Sciences GmbH
Sex: All
Age: 18 - 70+
Code: NCT07039916
Phase 3, Recruiting
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
for
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Location: Foxboro MA
Sponsor: Neurology Center of New England P.C.
Sex: All
Age: 55 - 70+
Code: NCT06681623
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
for
Non-Small Cell Lung Cancer
Location: Foxborough MA, Brighton MA, Boston MA, Milford MA,
Sponsor: Summit Therapeutics
Sex: All
Age: 18+
Code: NCT06767514
Phase 3, Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
for
Atrial Fibrillation (AF)
Location: Foxborough MA, Staten Island NY, Sherbrooke, Longueuil,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07626411
Phase 3, Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
for
Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies,